Comparative Pharmacology
Head-to-head clinical analysis: CABOMETYX versus PONLIMSI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CABOMETYX versus PONLIMSI.
CABOMETYX vs PONLIMSI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cabozantinib is a small molecule inhibitor of multiple receptor tyrosine kinases, including MET, VEGFR2, RET, AXL, KIT, and FLT3. It inhibits tumor growth, angiogenesis, and metastasis by blocking these pathways.
Ponlimsi is a small molecule inhibitor of the bromodomain and extraterminal (BET) family of proteins, specifically BRD2, BRD3, BRD4, and BRDT. It binds to acetyl-lysine recognition motifs, displacing BET proteins from chromatin, thereby inhibiting transcription of oncogenes such as MYC and BCL2.
60 mg orally once daily for the first 21 days of a 21-day cycle, with or without food, for renal cell carcinoma; for hepatocellular carcinoma, 60 mg orally once daily.
100 mg IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
None Documented
None Documented
Terminal half-life approximately 99 hours (range 80–120 h). Supports once-daily dosing with steady-state achieved within 15 days.
Terminal half-life is 24 hours (range 20-28 h), supporting once-daily dosing.
Primarily fecal (54%) with minimal renal excretion (27% unchanged drug; <10% as metabolites). Biliary excretion contributes to fecal elimination.
Primarily renal (60% unchanged) and biliary (30% as metabolites), with 10% fecal.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor